Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of IG-001 vs Nab-paclitaxel in Metastatic or Locally Recurrent Breast Cancer
NCT02064829Completed
- Sponsor
- Sorrento Therapeutics
- Start
- Mar 2014
- Primary completion
- Feb 2015
- Modality
- Cytokines & Interferons, Fc-Fusion Proteins
- Countries
- 7
01
Overview
Randomised, open-label trial of Paclitaxel Micelles for Injection in breast cancer (2 arms), sponsored by Sorrento Therapeutics. Primary endpoints: Maximum observed concentration of paclitaxel and Area under the concentration-time curve from time zero to infinite time. Started Mar 2014; status: completed.
02
Drugs
Paclitaxel Micelles for Injection
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02064829.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02064829.